Clinical trial • Phase I • Oncology
LY4175408 for Solid tumor | Cancer
Phase I trial of LY4175408 for Solid tumor | Cancer. 241 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Solid tumor | Cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 13-06-2025
- First CTIS Authorization Date
- 29-09-2025
Trial design
Phase I trial in France, Spain.
- Target Sample Size
- 241
Eligibility
Recruits 241 Vulnerable population selected; no details on consent or assent handling are provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling are provided in the record.
Recruitment
- Planned Sample Size
- 241
- Recruitment Window Months
- 43
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 80
France
- Earliest CTIS Part Ii Submission Date
- 02-09-2025
- Latest Decision Or Authorization Date
- 29-09-2025
- Processing Time Days
- 27
- Number Of Sites
- 2
- Number Of Participants
- 40
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- DITEP
- Contact Person Name
- Kaissa Ouali
- Contact Person Email
- kaissa.ouali@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Philippe Cassier
- Contact Person Email
- Philippe.Cassier@lyon.unicancer.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 06-08-2025
- Latest Decision Or Authorization Date
- 01-10-2025
- Processing Time Days
- 56
- Number Of Sites
- 2
- Number Of Participants
- 40
Sites
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology
- Contact Person Name
- Santiago Ponce Aix
- Contact Person Email
- santiago.ponce@oncosur.org
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY4175408
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)